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DOI 10.1186/s13024-017-0176-xRESEARCH ARTICLE Open AccessPhosphorylation of tau at Y18, but not tau-
fyn binding, is required for tau to modulate
NMDA receptor-dependent excitotoxicity in
primary neuronal culture
Takashi Miyamoto1,2, Liana Stein1,2, Reuben Thomas3, Biljana Djukic1, Praveen Taneja1, Joseph Knox1,
Keith Vossel1,2 and Lennart Mucke1,2*Abstract
Background: Hyperexcitability of neuronal networks can lead to excessive release of the excitatory neurotransmitter
glutamate, which in turn can cause neuronal damage by overactivating NMDA-type glutamate receptors and related
signaling pathways. This process (excitotoxicity) has been implicated in the pathogenesis of many neurological
conditions, ranging from childhood epilepsies to stroke and neurodegenerative disorders such as Alzheimer’s disease
(AD). Reducing neuronal levels of the microtubule-associated protein tau counteracts network hyperexcitability of
diverse causes, but whether this strategy can also diminish downstream excitotoxicity is less clear.
Methods: We established a cell-based assay to quantify excitotoxicity in primary cultures of mouse hippocampal
neurons and investigated the role of tau in exicitotoxicity by modulating neuronal tau expression through genetic
ablation or transduction with lentiviral vectors expressing anti-tau shRNA or constructs encoding wildtype versus
mutant mouse tau.
Results: We demonstrate that shRNA-mediated knockdown of tau reduces glutamate-induced, NMDA receptor-
dependent Ca2+ influx and neurotoxicity in neurons from wildtype mice. Conversely, expression of wildtype mouse tau
enhances Ca2+ influx and excitotoxicity in tau-deficient (Mapt−/−) neurons. Reconstituting tau expression in Mapt−/−
neurons with mutant forms of tau reveals that the tau-related enhancement of Ca2+ influx and excitotoxicity depend
on the phosphorylation of tau at tyrosine 18 (pY18), which is mediated by the tyrosine kinase Fyn. These effects are
most evident at pathologically elevated concentrations of glutamate, do not involve GluN2B–containing NMDA
receptors, and do not require binding of Fyn to tau’s major interacting PxxP motif or of tau to microtubules.
Conclusions: Although tau has been implicated in diverse neurological diseases, its most pathogenic forms remain to
be defined. Our study suggests that reducing the formation or level of pY18-tau can counteract excitotoxicity by
diminishing NMDA receptor-dependent Ca2+ influx.
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Experimental reduction of the microtubule-associated
protein tau counteracts neural network hyperexcitability
of diverse causes, including in animal models of severe
childhood epilepsy and aging-related neurodegenerative
disorders such as Alzheimer’s disease [1–7]. Conversely,
neuronal overexpression of tau promotes network hyper-
excitability [8–10]. Network hyperexcitability can lead to
excessive release of excitatory neurotransmitters such as
glutamate, which can cause neuronal injury and degener-
ation by overactivating NMDA-type glutamate receptors
(NMDARs) and related signaling pathways (excitotoxicity)
[11, 12]. Thus, excitotoxicity may be a key mechanism
linking hyperexcitability and tau to neurodegeneration.
Multiple lines of evidence support the notion that
tau plays a critical role in NMDAR-dependent excito-
toxicity. For example, overexpression of human tau
caused excitotoxicity in neuronal cultures [13]. In
turn, glutamate-induced excitotoxicity increased tau
expression [14, 15] and phosphorylation [16]. How-
ever, whereas the ability of tau reduction to suppress
network hyperexcitability has been confirmed by mul-
tiple groups (see above), the potential of this strategy
to suppress excitotoxicity has received less attention.
Pizzi et al. [17] reported that pre-treating cultures of
cerebellar granule cells with an anti-tau antisense
oligonucleotide (ASO) for 1 h before exposing them
to high concentrations of glutamate for 15 min re-
duced cell loss measured 24 h later. In light of the
long half-life of tau [18–20], it is not surprising that
this brief ASO treatment did not decrease baseline
tau levels. Although the ASO did prevent acute,
glutamate-induced increases in tau immunostaining, it
is possible that its excitoprotective effect resulted
from off-target effects. Furthermore, tau reduction in
primary neurons did not affect kainate-induced cal-
cium influx [7], another cause of excitotoxicity. Thus,
more work is needed to define the roles of tau and
tau reduction in excitotoxicity.
Although the exact mechanisms by which tau
reduction counteracts network hyperexcitability, and
possibly also downstream excitotoxicity, remain to be
defined, several lines of evidence suggest that these
mechanisms may involve Fyn. Fyn is a member of the
Src family of tyrosine kinases [21]. It can phosphorylate
tau at its tyrosine 18 residue to generate pY18-tau [22]
and can bind to tau through one or more proline-rich
(PxxP) motifs in tau [23–27]. Fyn can also modulate the
phenotype of transgenic mice overexpressing human
amyloid precursor proteins (hAPP) and hAPP-derived
amyloid-β (Aβ) peptides in neurons. Like humans with
AD [28, 29], these mice show evidence for network hy-
perexcitability, and suppression of this network hyperex-
citability by tau reduction or treatment with theantiepileptic drug levetiracetam prevents or ameliorates
synaptic and behavioral abnormalities in these models
[1, 2, 30]. Neuronal overexpression of Fyn exacerbates
network hyperexcitability and behavioral abnormalities
in hAPP mice [31], whereas Fyn ablation reduces their
synaptic impairments [32, 33].
Fyn phosphorylates the NMDAR subunit GluN2B at
Y1472 [34, 35], which strengthens the interaction be-
tween NMDARs and PSD-95 in the postsynaptic density
(PSD) [36] and enhances the activity of GluN2B–con-
taining NMDARs [35]. Genetic ablation of tau in Mapt
−/− mice has been reported to decrease the levels of Fyn
in neuronal dendrites and synaptosome preparations,
and to reduce the level of GluN2B phosphorylation at
Y1472 [3]. These and other findings led Ittner et al. to
hypothesize that tau enables interactions between Fyn
and GluN2B through a process that involves binding of
tau to Fyn and that tau reduction suppresses excitotoxi-
city by preventing Fyn from gaining access to GluN2B
[3]. However, consistent with results obtained by others
[2, 37], their electrophysiological recordings in acute
hippocampal slices revealed that tau ablation did not
change excitatory postsynaptic currents (EPSCs) or
AMPA/NMDA current ratios, which seems at odds with
the proposed hypothesis [3].
Here we used a primary neuronal culture model to
further investigate the roles of tau and tau-Fyn interac-
tions in glutamate-induced excitotoxicity, as well as the
extent to which tau reduction can prevent this type of
neurotoxicity, which has been implicated in a broad
range of neurological diseases [11, 12].
Results
To determine if tau has a role in excitotoxicity, we first
established a potentially scalable cell-based assay to quan-
tify excitotoxicity in cultures of primary mouse hippocam-
pal neurons (hereafter referred to simply as “neurons”).
For this purpose, we treated neurons with increasing con-
centrations of glutamate for 15 min, removed the glutam-
ate, and measured reductions in mitochondrial activity
24 h later by alamarBlue assay as a surrogate marker of
excitotoxic neuronal injury. Such short-term glutamate
treatments are commonly used to study neurotoxicity
[38–41] and could be relevant to the timeframe during
which elevations in glutamate levels occur under patho-
logical conditions, for example, as a result of surges in Aβ
levels [42–45] or during seizures [46].
The alamarBlue assay uses resazurin, an oxidation-
reduction indicator [47], to determine mitochondrial
activity, which is altered by exposure of neurons to
excitotoxic doses of glutamate [48, 49]. AlamarBlue
fluorescence is more sensitive than other indicators of
cytotoxicity [50–52] and, in neuronal cultures, changes
linearly with cell number and decreases in response to
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glucose deprivation, and abnormally low extracellular
potassium levels [53]. Because glutamate dose is a crit-
ical determinant of excitotoxicity [12], we ensured that
the assay covered a broad range of glutamate concentra-
tions (0–500 μM).
As expected [12, 54], glutamate exposure resulted in
dose-dependent neurotoxicity (Fig. 1). Consistent with
the prominent role of NMDARs in excitotoxicity [12]
and the mode of action of their antagonists [55–59],
the non-competitive NMDAR antagonist MK801
blocked most of the neurotoxicity over a wide range of
glutamate concentrations (Fig. 1a), whereas the
competitive NMDAR antagonist APV was more effect-
ive at moderate than high concentrations of glutamate
(Fig. 1b). To assess the relative contribution of
GluN2B-containing NMDARs, which have been impli-
cated in excitotoxicity [12, 54], we applied Ro 25–6981
or ifenprodil, two non-competitive antagonists selective
for such receptors [60, 61]. These antagonists also were
only partly effective (Fig. 1c, d), consistent with other
findings suggesting that GluN2B–containing NMDARs
contribute to excitotoxicity more markedly at moderate
than high doses of NMDAR agonists [54]. DNQX, a
competitive antagonist of AMPA receptors (AMPARs),
and tetrodotoxin (TTX), a sodium channel blocker, did
not significantly attenuate neurotoxicity in our assay
(Fig. 1e, f ), although both drugs were bioactive
(Additional file 1: Figure S1). Depletion of extracellular
Ca2+ also shifted the dose-response curve to the right
(Additional file 2: Figure S2A), consistent with the
dependence of excitotoxicity on Ca2+ influx through
NMDARs [12]. These findings agree with those of
others indicating that AMPARs and neuronal activity
are not required for excitotoxicity to occur [49, 62].
In line with the predominant role of NMDARs in
excitotoxicity, the selective NMDAR agonist NMDA was
as neurotoxic as glutamate (Additional file 2: Figure
S2B). Although blocking AMPARs did not diminish
glutamate-induced neurotoxicity (Fig. 1e), two AMPAR
agonists, AMPA and L-quisqualic acid, caused
intermediate levels of neurotoxicity in our assay
(Additional file 2: Figure S2B). In contrast, the kainate
receptor (KAR) agonist kainic acid elicited neurotoxicity
only at very high doses, and the selective group I mGluR
agonist (S)-3,5-DHPG had minimal effects (Additional
file 2: Figure S2B).
To evaluate the relation of our neurotoxicity measure-
ments to cell loss, we treated primary neuronal cultures
with glutamate as above, confirmed glutamate-induced
neurotoxicity by alamarBlue assay 24 h later, fixed and
immunostained the cultures for the neuronal marker
NeuN [63] and the astroglial marker glutamine synthe-
tase [64], and counted the number of immunoreactivecells. Glutamate concentrations between 10 and 100 μM
resulted in dose-dependent loss of neurons, but not as-
trocytes (Fig. 1g, h). In all subsequent experiments, we
used the alamarBlue assay to evaluate neurotoxicity be-
cause it facilitates the quantitative analysis of multiple
neuronal cultures and conditions.
Reduction of tau through lentiviral expression of
anti-tau shRNA (shTau) significantly reduced
glutamate-induced toxicity in neurons from wildtype
but not tau-deficient (Mapt−/−) mice (Fig. 2a-c,
Additional file 3: Figure S3), particularly in the glutam-
ate dose range in which we had observed neuronal loss
in uninfected wildtype cultures (Fig. 1g, h). Knock-
down with shTau reduced endogenous mouse tau
(mTau) by ~50% (Fig. 2c). Conversely, lentiviral ex-
pression of wildtype 0N4R mTau (mTauWT) exacer-
bated glutamate-induced neurotoxicity in Mapt−/− but
not wildtype neurons (Fig. 2d-f ). These results suggest
that tau contributes to excitotoxicity, especially in the
presence of high glutamate concentrations.
Because Ca2+ influx through NMDARs critically
contributes to excitotoxicity (Fig. 1a, Additional file 2:
Figure S2A, and [49, 62]), we wondered whether tau
might promote this process. To assess this possibility,
we measured intracellular Ca2+ levels by live-cell Ca2+
imaging in neurons. We exposed neurons to increasing
concentrations of NMDA while blocking voltage-gated
Ca2+ channels (VGCC) (Fig. 3a), the other major route
of Ca2+ entry into neurons [65, 66]. In this paradigm,
tau reduction decreased, whereas tau overexpression in-
creased NMDAR-dependent Ca2+ influx (Fig. 3b, c). Col-
lectively, these results suggest that tau contributes to
excitotoxicity, at least in part, by enhancing the cell sur-
face levels or conductance of NMDARs.
How might tau affect NMDARs? Ittner and colleagues
proposed that tau-dependent transport of the tyrosine kin-
ase Fyn to the PSD and subsequent phosphorylation of
GluN2B by Fyn may modulate neuronal excitability and
mediate Aβ-induced neuronal dysfunction [3]. However,
Ro 25–6981 did not block the exacerbation of excitotoxi-
city caused by expression of mTauWT in Mapt−/− neurons
(Fig. 4a, b), making it unlikely that the contribution of tau
to excitotoxicity depends on GluN2B–containing
NMDARs, at least in our cell culture model.
Notably, Fyn has multiple substrates and functions
[21], raising the possibility that interactions between tau
and Fyn [23–27] might contribute to Aβ-induced neur-
onal dysfunction [2, 31–33] and excitotoxicity in ways
that do not depend on the phosphorylation of GluN2B
by Fyn. To test this hypothesis, we constructed several
viral vectors that encode 0N4R mTau bearing distinct
mutations in putative Fyn interaction domains (Fig. 5a):
substituting the single tyrosine residue that can be phos-
phorylated by Fyn [22] with phenylalanine (mTauY18F),
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Fig. 1 Glutamate-induced neurotoxicity depends on NMDARs. a-f Neurons from wildtype (WT) mice were exposed to different
concentrations of glutamate for 15 min at DIV13. Relative levels of survival were quantified by alamarBlue assay 24 h later. Cultures were
treated with vehicle or different antagonists starting 1 h before the glutamate exposure: a non-competitive NMDAR antagonist MK801 (20 μM), b
competitive NMDAR antagonist APV (50 μM), non-competitive GluN2B-selective NMDAR antagonists c Ro 25–6981 (1 μM) or d ifenprodil (10 μM),
e competitive AMPAR antagonist DNQX (20 μM), or f sodium channel blocker tetrodotoxin (TTX, 1 μM). The boxplots represent the distribution of
the differences in mean fluorescence between antagonist- vs. vehicle-treated neurons at each dose across independent experiments. The lower
and upper ends of the boxes represent the 25th and 75th quartile of each distribution, respectively. The horizontal line in each box represents the
median. The ends of the whiskers terminate at the farthest points that are within 1.5 times the inter-quartile range (difference between upper and
lower ends of the box). Individual dots shown in some of the panels represent outliers that fell outside the range defined by the whiskers.
Consequently, the curve in a indicates that the survival-promoting effects of MK801 became more and more evident as glutamate concentrations
increased, whereas the bell-shaped curves in b–d indicate that, at the particular concentrations used, the respective antagonists were protective at
moderate, but not higher, concentrations of glutamate. Numbers of independent experiments (n) with cumulative well numbers per condition in
parentheses: a 4 (24–32), b 10 (76–80), c 9 (68–72), d 8 (56–64), e 9 (70–72), and f 4 (30–32). When comparing mean differences across all doses
within any given panel, a one-sided, one-sample t-test revealed significant differences between experimental and control conditions in (a, P < 0.05),
(b, P < 0.0001), (c, P < 0.001), and (d, P < 0.001). g, h Neuronal cultures were treated with glutamate at DIV13 and fixed 24 h later, followed by
immunostaining for the neuronal marker NeuN and the astroglial marker glutamine synthetase and nuclear staining with Hoechst33342.
g Representative photomicrographs of immunolabeled cultures imaged on an ArrayScan XTI Live High Content Platform. Scale bar: 200 μm. h Number
of Hoechst33342-positive cells per well that were immunoreactive for NeuN or glutamine synthetase. n = 4 independent experiments, each of which
included 8–16 wells per condition. Data in h are means ± SEM
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binding PxxP motifs [24–27] to alanines (mTauAxxA6
and mTauAxxA7, respectively), and deleting both the
repeat domain and the C-terminal domain (mTauΔ74).
Overexpression of human TauΔ74 (hTauΔ74) has been
reported to sequester Fyn from the PSD and to reduce
neuronal and cognitive dysfunction in hAPP transgenic
mice [3]. To further assess the role of the repeat domain,
which is critical for the binding of tau to microtubules
[67], we also generated mTau constructs that lack this
domain (mTauΔRD) or have duplicate repeat domains
(mTau8RD) [68, 69].
The interaction between tau and Fyn has been studied
mostly in a cell-free system [24] and by co-
immunoprecipitation [3, 23] using tagged hTau and an
SH2 or SH3 fragment of Fyn [24–27]. To determine
whether mTau interacts with endogenous Fyn in cul-
tured neurons and assess how mutations in mTau affect
their interaction, we used a proximity ligation assay
(PLA), which enables in situ detection of two antigens in
close proximity (<40 nm) (Additional file 4: Figure S4)
[68, 70, 71]. In this assay, the antigens are labeled with
primary antibodies, which are then bound by two sec-
ondary antibodies coupled with DNA strands that can li-
gate when in close proximity. The ligated sequence
serves as an elongation template for quantitative PCR,
whose product is labeled and detected by fluorescent
probes [70]. Using this assay on Mapt−/− neuronal cul-
tures transfected with the mTau constructs shown in
Fig. 5a, we made the following observations. Mutation of
Y18 or either PxxP motif reduced the association be-
tween total tau and Fyn, whereas deletion of the repeat
domain—by itself or in conjunction with the C-terminal
domain—did not (Fig. 5b). These findings provide fur-
ther support for the importance of Y18 and both PxxPmotifs in Fyn-tau interactions and suggest that these in-
teractions do not require binding of tau to microtubules.
In fact, because mTau8RD bound more tightly to micro-
tubules [68, 69] but less tightly to Fyn (Fig. 5b) than
mTauWT, Fyn may interact primarily with tau that is not
bound to microtubules and binding of tau to microtu-
bules may diminish its chances of interacting with Fyn.
We also assessed the association of Fyn with tau
that is unphosphorylated at residues S198, S199 and
S202 (detected with the Tau1 antibody), an interaction
that has remained controversial [23–27]. Mutation of
Y18 and deletion of the repeat domain increased the
association between this type of tau and Fyn, whereas
the AxxA7 mutation decreased it, and no significant
effects were observed as a result of the AxxA6 muta-
tion, deletion of the repeat domain together with the
C-terminal domain, or duplication of the repeat do-
main (Fig. 5b). These findings suggest that interac-
tions between “unphosphorylated” tau and Fyn
depend on only one of the two PxxP motifs and may
be diminished by Y18 phosphorylation and binding of
tau to microtubules.
All mTau constructs also encoded GFP, which was
linked to mTau via a self-cleaving P2A peptide (GFP-
P2A-mTau, Additional file 4: Figure S4A). This strat-
egy can be expected to result in the production of
mTau and GFP as separate proteins at a 1:1 molar ra-
tio [72–75]. To control for differences in the expres-
sion of constructs across transfected neurons, we
used GFP signals to normalize our measurements of
mTau levels. Based on these measurements, we found
that the AxxA6, Δ74 and ΔRD mutations decreased
the relative levels of total and “unphosphorylated” tau,
whereas the AxxA7 and 8RD modifications changed
the relative abundance of these tau species in
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Fig. 2 Tau modulates glutamate-induced excitotoxicity in cultured neurons. Glutamate-induced neurotoxicity in neuronal cultures from WT
or tau-deficient (Mapt−/−) mice was assessed as in Fig. 1. Some cultures were transduced with lentiviral vectors encoding shRNA against tau
(shTau) or scrambled shRNA (shSCR) at the day of plating or with lentiviral vectors encoding GFP-P2A-mTauWT or GFP-P2A at DIV7, as indicated. a,
b Expression of shTau improved survival in WT a but not Mapt−/− b cultures. c Relative tau levels in WT and Mapt−/− cultures expressing shSCR or
shTau were determined by western blot analysis with the pan-tau antibody EP2456Y and densitometric analysis of tau signals. Mean tau levels in
shSCR-expressing WT cultures were arbitrarily defined as 1.0. d, e Overexpression of mTauWT increased glutamate-induced neurotoxicity (i.e.,
decreased survival) in WT d and Mapt−/− e cultures. f Relative tau levels in WT and Mapt−/− cultures expressing GFP-P2A or GFP-P2A-mTauWT were
determined as in c. Mean tau levels in GFP-P2A-expressing WT cultures were arbitrarily defined as 1.0. Numbers of independent experiments (n)
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by two-way ANOVA and Tukey test. Boxplots were explained in Fig. 1. Data in c, f are means ± SEM
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tau to microtubules (Δ74 and ΔRD) decreased tau
levels, consistent with previous findings [3, 68, 69].
Interestingly, the AxxA7 mutation, which markedly
reduced interactions of Fyn with both total and
“unphosphorylated” tau (Fig. 5b), decreased the levels
of total tau but prominently increased the levels of
“unphosphorylated” tau (Fig. 5c). Underlying mecha-
nisms may include changes in the stability, turnover
or posttranslational modification of the respective tau
species and deserve to be further explored.
To determine whether tau-Fyn interactions are
involved in the tau-dependent modulation of excitotoxi-
city, we focused on the Y18F mutation, which disruptsFyn-dependent phosphorylation of tau at this residue
[23] and the AxxA7 mutation, which interferes with the
binding of tau to Fyn (Fig. 5b) [3, 24]. Neurons from
Mapt−/− mice were transduced with lentiviral vectors
expressing mTauWT, mTauY18F, a phosphomimetic
mutant at the Y18 residue (mTauY18E), or mTauAxxA7,
followed by exposure to glutamate and the neurotoxicity
assay. At >30 μM of glutamate, mTauWT, mTauY18E and
mTauAxxA7 similarly increased glutamate-induced neuro-
toxicity beyond levels in GFP-P2A-expressing tau-
deficient neurons, whereas mTauY18F was significantly
less effective (Fig. 6a-d). All of these mTau proteins were
expressed at comparable levels (Fig. 6e). In Mapt−/− neu-
rons exposed to NMDA in the presence of VGCC
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dependent Ca2+ influx less than expression of mTauWT
(Fig. 6f ).
Discussion
These results suggest that tau promotes glutamate-
induced excitotoxicity by increasing NMDAR-dependent
Ca2+ influx and that Fyn-mediated phosphorylation of
tau at Y18 enhances this process at high concentrations
of glutamate. These effects did not involve GluN2B-
containing NMDARs and did not require binding of
Fyn to tau’s major interacting PxxP motif or of tau to
microtubules. In addition to these novel findings, weconfirmed that glutamate-induced excitotoxicity is
inhibited by 50% reduction of tau [1, 3, 17] and exac-
erbated by overexpression of tau [9, 10].
We assessed excitotoxicity over a wide range of
glutamate concentrations because it is difficult to know
how glutamate concentrations in primary neuronal
cultures relate to those in the intact or diseased brain.
On one hand, the isolation of primary neurons from the
brain environment exposes them to many stresses that
could increase their susceptibility to excitotoxicity. On
the other hand, their culture medium contains numer-
ous neuroprotective factors that could diminish the
neurotoxic impact of any given glutamate concentration.
−1250
−1000
−750
−500
−250
0
1 10 30 50 100 500
−1250
−1000
−750
−500
−250
0
1 10 30 50 100 500
a b
[Glutamate] (µM) [Glutamate] (µM)
ecnereffi
D
yt isnet nI
n ae
M
A2
P-
P
F
G.sv
ua
T
m-
A2
P-
P
F
G
ecnereffi
D
ytisnetnI
nae
M
A 2
P -
P
F
G.sv
ua
T
m-
A2
P-
P
F
G
Ro 25-6981Vehicle
Fig. 4 Enhancement of glutamate-induced excitotoxicity by tau does not depend on GluN2B/2B–containing NMDARs. a, b Glutamate-induced
neurotoxicity in Mapt−/− neurons transduced with lentiviral vectors encoding GFP-P2A-mTauWT or GFP-P2A was assessed as in Figs. 1 and 2. For 1 h
before and throughout the glutamate exposure, neurons were treated with a vehicle or b Ro 25–6981 (1 μM). Numbers of independent experiments
(n) with cumulative well numbers per condition in parentheses: a 3 (23–24) and b 4 (28–32). When comparing mean differences across all doses within
any given panel, a one-sided, one-sample t-test revealed significant differences between experimental and control conditions in (a: P < 0.05) and
(b: P < 0.05)
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amino acid, but its levels vary widely depending on the
exact location. Intracellular glutamate concentrations in
the brain are in the millimolar range [76]. The concen-
tration of glutamate in the synaptic cleft ranges from 0.5
to 1.0 mM [77]. The extracellular concentration of glu-
tamate is normally kept in the low micromolar range,
for example, at 2 μM in the hippocampus [78], 9 μM in
the cortex [76], and 10 μM in the CSF [79]. However,
glutamate concentrations probably vary more widely in
the complex pathological microenvironments of AD
brains, the penumbra of an ischemic infarct, and brain
regions affected by epileptic seizures. Compared with
controls, glutamate levels were increased ~1.3-fold in
the CSF of AD patients [80] and ~2-fold in the extracel-
lular space of the hippocampus of mice overexpressing
human APP, which simulate key aspects of AD [44].
Even greater increases in glutamate concentrations may
occur in AD brains within and around synaptic clefts:
soluble Aβ oligomers, which accumulate in AD brains
[81–83], elicit glutamate release from astrocytes [44] and
microglia [45], and prevent excitatory amino acid trans-
porters from clearing extracellular glutamate by nega-
tively affecting their expression or function [43, 84, 85].
Bilateral intrahippocampal microdialysis in humans re-
vealed that extracellular glutamate concentrations can
be in the 100–500 μM range for over 15 min duringseizures [46]. The experimental conditions under which
we observed protective effects of tau reduction may be
relevant to some or all of these pathophysiological
scenarios.
Indeed, the excitoprotective effects of tau reduction
we observed in this study were most evident at patho-
logically elevated concentrations of glutamate. At lower
concentrations of glutamate, tau reduction had no effect
on multiple outcome measures, including NMDA-
induced Ca2+ influx. These observations are consistent
with in vivo studies demonstrating that reduction or ab-
lation of tau has minimal or no effects on neuronal ac-
tivities unless pathological conditions are introduced
that cause network hyperexcitability [1–6, 86]. While
these studies indicate that tau reduction counteracts net-
work hyperexcitability of diverse causes, the current
study suggests that tau reduction may also counteract
the excitotoxic neuronal injury to which network hyper-
excitability can lead, highlighting the broad potential of
this therapeutic strategy.
High concentrations of glutamate are associated with
an increased opening time of NMDARs [87], which may
explain, at least in part, why the effects of tau modula-
tion were most evident at high doses of glutamate. It is
noteworthy in this context that our measurements may
have underestimated tau-dependent changes in
NMDAR-dependent Ca2+ influx. We selected FLIPR
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Fig. 5 Tau mutations that modulate interactions between tau and Fyn. a Diagram indicating deletion and point mutations in 0N4R mTau and
corresponding residues in 2N4R hTau in parentheses. Epitopes of the Tau1 and Tau5 antibodies are indicated also. b Interactions between Fyn
and exogenous tau in transfected Mapt−/− neurons were determined by proximity ligation assay (PLA) using the Fyn3 antibody in combination
with the Tau5 (left) or Tau1 (right) antibodies. Tau5 detects total tau, whereas Tau1 detects tau that is unphosphorylated at residues S198, S199
and S202. The closeness of interactions between Fyn and tau was expressed relative to measurements obtained in Mapt−/− neurons transfected
with GFP-P2A-mTauWT (WT). The other cultures were transfected with similar constructs in which mTauWT was replaced by the indicated tau
mutants. n = 16–31 neurons per construct from two experiments (three different neurites were quantified and averaged per individual transfected
neuron). c The abundance of tau in transfected (GFP-positive) Mapt−/− neurons was estimated based on relative immunofluorescence intensities
detected after staining of cultures with Tau5 (left) or Tau1 (right) and normalization to GFP signals. Average levels in GFP-P2A-mTauWT
(WT)-transfected cultures were arbitrarily defined as 1.0. *P < 0.05, **P < 0.01, ****P < 0.0001 vs. WT by one-way ANOVA and Bonferroni test. Data
are means ± SEM
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(See figure on previous page.)
Fig. 6 Phosphorylation of mTau at Y18 is required for tau to modulate glutamate-induced excitotoxicity. a-d Neurons from Mapt−/− mice were
transduced with lentiviral vectors expressing GFP-P2A or GFP-P2A-mTau constructs encoding a mTauWT, b mTauY18F, c mTauY18E, or d mTauAxxA7 on
DIV7. Glutamate-induced neurotoxicity was assessed as in Figs. 1 and 2. Numbers of independent experiments (n) with cumulative well numbers per
condition in parentheses: a 10 (71–80), b 7 (47–56), c 4 (29–32), and d 5 (29–40). When comparing mean differences across all doses within any given
panel, a one-sided, one-sample t-test revealed significant differences between experimental and control conditions in (a, P < 0.01), (c, P < 0.01) and
(d, P < 0.01), but not (b, P = 0.12). e Relative tau levels in vehicle-treated cultures from a–d were determined by western blot analysis with the pan-tau
antibody EP2456Y. Mean tau levels in GFP-P2A-mTauWT-expressing Mapt−/− cultures were arbitrarily defined as 1.0. One-way ANOVA revealed no
significant differences in tau expression levels across cultures. Data are means ± SEM. f Mapt−/− neurons were transduced with lentiviruses encoding
GFP-P2A-mTauWT or GFP-P2A-mTauY18F on DIV7 and analyzed for NMDA-induced increases in intracellular Ca2+ in the presence of VGCC blocker cocktail
on DIV 14 as in Fig. 3. Numbers of independent experiments (n) with cumulative well numbers per condition in parentheses: 4 (12). When comparing
mean differences across all doses, a one-sided, one-sample t-test revealed significant differences between mTauY18F and mTauWT (P < 0.01)
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a high quantum yield as well as a broad signal window
and amplitude. However, because this indicator can be-
come saturated at high intracellular Ca2+ concentrations,
it may not be optimal for detecting changes in Ca2+ in-
flux at the high glutamate concentrations at which tau
modulation has the most marked effects on excitotoxi-
city. Furthermore, our Ca2+ imaging assay measured
overall cytosolic Ca2+ levels, whereas the effects of tau
modulation on intracellular Ca2+ levels might be con-
fined to specific subcellular regions that are particularly
critical for downstream signaling such as the area near
the mouth of NMDARs [88]. Although Ca2+ influx plays
an important role in excitotoxicity [11, 12, 89], depletion
of extracellular Ca2+ only partially protected against
excitotoxicity in our model, possibly because we
returned our neurons to Ca2+-containing medium right
after the glutamate exposure. Ca2+-independent metabo-
tropic functions of NMDA receptors could also contrib-
ute to cellular toxicity [90]. It should also be noted that
glutamate-induced excitotoxicity may depend less on
extracellular and cytoplasmic Ca2+ levels than on mito-
chondrial Ca2+ levels [11, 91–93], which we did not
measure. Thus, the relationship between tau, Ca2+
homeostasis, and excitotoxicity is probably complex and
deserves further investigation.
The mTauWT-dependent enhancement of glutamate-
induced neurotoxicity in our neuronal cultures did not
depend on GluN2B–containing NMDARs, as it was
observed in the absence (Figs. 2, 4, and 6) or presence
(Fig. 4) of Ro-25-6981. Because the NMDAR subunit
composition in cultured neurons changes from contain-
ing more GluN2B to containing more GluN2A [94] and
our DIV13 neuronal cultures may still be in this transi-
tion, we cannot exclude the possibility that this tau ef-
fect occurs in maturing, but not adult, neurons.
However, DIV12–14 is a standard time point for meas-
uring excitotoxicity [95–97], and the GluN2B-to-
GluN2A subunit transition at this time point is largely
completed [98, 99]. Moreover, treatment with Ro 25–
6981 or ifenprodil attenuated glutamate-induced excito-
toxicity in our cultures at moderate but not high dosesof glutamate, consistent with results obtained in cortical
neurons at DIV18 [54].
Because TauY18F was unable to enhance excitotoxicity
at high glutamate concentrations, a potential excitopro-
tective strategy may be to inhibit phosphorylation of tau
by Fyn, a process that appears to be restricted to Y18
[22]. In principle, this could be achieved by inhibiting
the kinase activity of Fyn. However, although several in-
hibitors of other members of the Src kinase family have
been developed for the treatment of cancer [100] and
one of these inhibitors is being tested in a clinical trial
for AD [101, 102], we are unaware of drugs that select-
ively inhibit Fyn, but none of the other members of the
Src kinase family, and that also effectively penetrate the
blood-brain barrier. Furthermore, like the other mem-
bers of this family, Fyn has diverse substrates and has
been implicated in multiple pathways that affect neur-
onal functions [102–104]. Genetic ablation of Fyn in
mice did not cause overt phenotypes but reduced cal-
cium flux in thymocytes [105], impaired LTP in the ol-
factory bulb and hippocampus [106, 107], and caused
spatial learning deficits [106]. Heterozygous Fyn knock-
out mice had no detectable behavioral or anatomical
deficits [107], suggesting that partial reduction of Fyn
may be well tolerated. Indeed, cognitive deficits and syn-
aptic depletion in APP/PS1 mice were reversed by treat-
ment with the Src family kinase inhibitor AZD0530,
which inhibits Fyn and is well tolerated in mice, dogs,
and humans [101, 102]. Other potential strategies in-
clude blocking protein-protein interactions that are re-
quired for Fyn to phosphorylate Y18 in tau, and
targeting downstream consequences of this posttransla-
tional modification.
The phosphomimetic Y18E substitution in mTau did not
increase glutamate-induced neurotoxicity beyond levels ob-
served with mTauWT. Although glutamate is commonly
used to mimic tyrosine phosphorylation, it should be noted
that glutamate and phosphorylated tyrosine show larger
structural differences than other phosphomimetic substitu-
tions (e.g., aspartate versus phosphorylated serine) [108],
which may have contributed, at least in part, to the negative
result we obtained with mTauY18E.
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disrupts binding of hTau to Fyn’s SH3 domain [25] but
is required for binding of hTau to Fyn’s SH2 domain [27].
In our PLA experiments, blocking Y18 phosphorylation of
mTau by mutagenesis shifted the interaction of Fyn from
“total” tau to “unphosphorylated” tau. By extrapolation, it
is possible that Y18 phosphorylation promotes the inter-
action of Fyn with tau species that are also phosphorylated
at residues S198, S199 and S202. Additional studies are
needed to test this hypothesis and to characterize the
intraneuronal distribution of pY18-tau. Other tau phos-
phorylations have been implicated in the enrichment of
tau in dendritic spines and in consequent alterations of
NMDARs [109–112]. In an extensive mass spectrometry
analysis of posttranslational tau modifications, we did not
detect pY18-tau in hippocampal and cortical homogenates
from WT or hAPP transgenic mice [113], suggesting that
this species was of low abundance or absent from these
tissues. Because pY18-tau may be confined to a small sub-
cellular compartment, its detection would likely require
the development of sensitive pY18-tau-specific antibodies
that are suitable for immunostaining of brain sections and
electron microscopy; to our knowledge, such antibodies
are currently not available. Closely related to the subcellu-
lar distribution of pY18-tau is the question of how this tau
species might increase NMDAR-dependent Ca2+ influx.
Possible mechanisms include interactions of tau with
NMDARs, regulators of NMDARs or other component of
the PSD, and the modulation of signaling pathways that
can increase intracellular Ca2+ levels. Additional studies
are needed to explore these nonexclusive possibilities.
Conclusions
Our findings suggest that neuronal tau accumulation pro-
motes and tau reduction counteracts glutamate-induced
excitotoxicity, most likely by modulating NMDAR-
dependent Ca2+ influx. The tau-dependent enhancement
of excitotoxicity requires phosphorylation of tau at its Y18
residue, which is mediated by Fyn, but does not dependTable 1 Antibodies used for western blotting (WB), immunocytoche
Antibody/Clone Target Source
AHB0042 (clone: Tau5) Tau Thermo
MAB10417 (clone: EP2456Y) Tau EMD Mi
MAB302 (clone: GS-6) Glutamine Synthetase EMD Mi
MAB3420 (clone: Tau1-PC1C6) Tau EMD Mi
MAB377 (clone: A60) NeuN EMD Mi
sc-16 (clone: Fyn3) Fyn Santa C
T5076-200UL (clone: SDL.3D10) βIII Tubulin Sigma-A
Secondary antibodies conjugated
with Alexa Fluor
Respective species
and isotype
Thermo
Secondary antibodies conjugated
with IRDye
Respective species
and isotype
LI-CORon interactions of Fyn with known Fyn-binding domains
in tau or on GluN2B/2B–containing NMDARs. Blocking
the phosphorylation of tau at Y18 may be excitoprotective,
particularly in pathological conditions associated with an
abnormal accumulation of tau, glutamate or both.
Methods
Reagents
Table 1 provides information on the antibodies and Table 2
on the pharmacological compounds used in this study.
Primary mouse hippocampal cultures
For the generation of primary cultures, we used male
and female WT mice and Mapt−/− mice [114] (kindly
provided by Dr. Hana Dawson, Duke University) on a
C57Bl/6 J background. Hippocampi of newborn pups
(P0–P1) were dissected in ice-cold Earle’s balanced salt
solution (EBSS), lacking CaCl2, MgSO4 and phenol red
(Thermo Fisher Scientific, 14155), digested with papain
(Worthington LK003176, ~1 unit per hippocampus) in
EBSS at 37 °C for 15 min, and triturated in a disposable
plastic tube in low ovomucoid solution: Dulbecco’s
phosphate-buffered saline (DPBS, Thermo Fisher
Scientific, 14040-182) containing 1.5 mg/ml BSA
(Sigma-Aldrich, A7030-10G), 1.5 mg/ml trypsin inhibi-
tor (Sigma-Aldrich, T9253-5G), and 66.7 units/ml
DNase I (Sigma-Aldrich, D5025). After removing debris
with a 70-μm nylon strainer (BD Biosciences, 352350),
neurons were spun at 1000 rpm for 5 min. Cell pellets
were gently dissociated in Neurobasal A medium supple-
mented with 1× B27 (Thermo Fisher Scientific, 17504–
044), 1× N2 (Thermo Fisher Scientific, 17502–048),
2.4 mM L-glutamine (Thermo Fisher Scientific, 25030–
081), and 100 units/ml penicillin/streptomycin (Thermo
Fisher Scientific, 15410–122). Cells were plated on poly-
D-lysine (PDL)-coated 12-well or 96-well plates at a
density of 500,000 or 60,000 neurons/well, respectively,
for western blot analyses or glutamate-induced excito-
toxicity assay, or 800,000 neurons/coverslip formistry (ICC), or proximity ligation assay (PLA)
Final Concentration/ Dilution Method
Fisher Scientific 1 μg/ml WB, ICC, PLA
llipore 0.1 μg/ml WB
llipore 1:1000 ICC
llipore 1 μg/ml WB, ICC, PLA
llipore 1:1000 ICC
ruz Biotechnology 1 μg/ml 4 μg/ml WB, PLA
ldrich 0.1 μg/ml WB
Fisher Scientific 2 μg/ml ICC
0.1 μg/ml WB
Table 2 Compounds (all from Tocris Biosciences)
Compound Catalog Number Solvent of Stock
(+)-MK 801 maleate 0924 Water
AMPA 0169 Water
DL-APV 0105 Water
DNQX 0189 DMSO
Ifenprodil 0545 Water
Kainic acid 0222 Water
L-Quisqualic acid 0188 1 eq. NaOH
Mibefradil 2198 Water
Nimodipine 0600 DMSO
NMDA 0114 Water
Ro 25–6981 maleate 1594 DMSO
(S)-3,5-DHPG 0805 Water
SNX 482 2945 Water
TTX 1078 Water
ω-agatoxin IVA 2799 Water
ω-conotoxin MVIIC 1084 Water
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placed with new medium every week. Neurons were
used for experiments at DIV 13–15. By DIV14, cultures
typically contained similar numbers of neurons and as-
trocytes (Fig. 1a, h).
Glutamate-induced excitotoxicity assay
Primary cells were plated on PDL-coated 96-well plates
(Greiner Bio-one, 655946) at a density of 60,000 cells
per well. Cultures were infected with lentiviral con-
structs encoding shRNA on the day of plating (DIV0) or
with lentiviral constructs encoding GFP-P2A or GFP-
P2A-mTau on DIV7. On DIV13, cells were treated with
various concentrations of glutamate dissolved in Neuro-
basal A medium with supplements (1× B27, 1× N2,
2.4 mM L-glutamine, and 100 units/ml penicillin/
streptomycin) or mock treated with Neurobasal A
medium with supplements for 15 min at 37 °C under 5%
CO2, followed by incubation conditioned medium previ-
ously collected from the same cultures. For Additional
file 2: Figure S2A, cells were exposed to glutamate in ei-
ther Ca2+-containing isotonic solution (vehicle [all in
mM]: 138 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES,
and 10 glucose) or in 0 mM Ca2+ solution (138 NaCl, 5
KCl, 1 MgCl2, 0.1 EGTA, 10 HEPES, and 10 glucose). At
24 h after glutamate treatment, conditioned medium
was replaced with pre-warmed HEPES-buffered solu-
tion (HBS [all in mM]: 119 NaCl, 2.5 KCl, 2 MgCl2,
2 CaCl2, 25 HEPES, and 30 glucose) containing 1×
alamarBlue (Thermo Fisher Scientific, DAL1100),
and cultures were incubated at 37 °C under 5% CO2
for 2–3 h. AlamarBlue fluorescence was thenmeasured with a fluorescence plate reader (Molecu-
lar Device, SpectraMax M5). Mock treated cells were
homogenized in RIPA lysis and extraction buffer
(Thermo Fisher Scientific, 89900) with Halt protease
and phosphatase inhibitor cocktail (Thermo Fisher
Scientific, 78447) to assess tau levels by western blot
analysis.
High content imaging
After the excitotoxicity assay, cultures were fixed with
4% paraformaldehyde and 4% sucrose in 1× phosphate
buffered saline (PBS) for 15 min at room temperature
(RT) and washed three times with 1× PBS. Fixed cells
were permeabilized with 0.2% Triton X-100 in 1× PBS
for 5 min and blocked with 10% normal goat serum
(NGS, Jackson Immunoresearch, 005–000–121) in 1×
PBS for 1 h at RT. They were then incubated with
primary antibodies against the neuron-specific marker
NeuN (Millipore, MAB377) and the glia-specific marker
glutamine synthetase (GS, Millipore, MAB302) in 1×
PBS containing 2% NGS for 1.5 h at RT. Cultures were
then washed three times with 1× PBS at RT and stained
with Hoechst33342 (1:5000 dilution, Thermo Fisher
Scientific, H3570) to visualize nuclei and with secondary
antibodies conjugated with Alexa Fluor546 (A-21123)
for NeuN or Alexa Fluor647 (A-21241) for GS (2 μg/ml,
Thermo Fisher Scientific) in 1× PBS containing 2% NGS
for 1 h at RT. Cultures were then washed three times
with 1× PBS and imaged on an ArrayScan XTI Live
High Content Platform (Thermo Fisher Scientific).
Twenty-one images were taken per well of a 96-well
plate using a 10× objective. Filter settings were 549–15
BGRFRN for Alexa Fluor546, 650–13 BGRFRN for
Alexa Fluor647, and 386–23 BGRFRN for
Hoechst33342. Exposure time for each channel was de-
termined with the built-in peak target (percentile)
method, so that target values were between 20% and
25%. After acquiring all images, the number of punctae
that were positive for Hoechst33342 and NeuN or GS
were counted using the colocalization program of HCS
Studio: Cellomics Scan Version 6.5.0 (Thermo Fisher
Scientific). Hoechst33342-positive punctae were deter-
mined using the following parameters. Smoothing: Uni-
form (Method: Value = 1), Thresholding: Isodata
(Method: Value = −0.25), Segmentation: Shape (Method:
Value = 1), and Object cleanup option on. Pre-defined
Hoechst33342-positive punctae that were also positive
for NeuN or GS were determined using primary object
mask modification (Mask type: Circle and Value = 1)
and the object selection option by defining the smallest
minima in the histograms of both Object.TotalIntensity
and Object.AvgIntensity as the low object selection
levels and the highest values as the high object selection
levels.
Table 3 Primers used
Y18F_s 5′- agaccatgctggagatttcactctgctccaagac -3’
Y18F_as 5′- gtcttggagcagagtgaaatctccagcatggtct -3’
Y18E_s 5′- gaagaccatgctggagatgagactctgctccaagacc -3’
Y18E_as 5′- ggtcttggagcagagtctcatctccagcatggtcttc -3’
AxxA6_s 5′- accccatccctagcaacaccggccacccgg -3’
AxxA6_as 5′- ccgggtggccggtgttgctagggatggggt -3’
AxxA7_s 5′- ggtccgcactcccgctaagtcagcatcagctagtaa -3’
AxxA7_as 5′- ttactagctgatgctgacttagcgggagtgcggacc -3’
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Neurons were plated on PDL-coated 96-well plates
(Greiner Bio-one, 655946) at a density of 80,000–120,000
neurons per well, and transduced with lentiviral vectors
encoding shRNA on the day of plating (DIV 0) or with
lentiviral vectors encoding GFP-P2A or GFP-P2A-mTau
at DIV7. At DIV14, neurons were incubated with fluores-
cent Ca2+ indicator (Molecular Devices, FLIPR Calcium 6
assay kits) in HBSS-Hepes buffer (1× Hank’s balanced salt
solution, 20 mM HEPES, 2.5 mM probenecid, 30 mM glu-
cose, and 50 μM glycine) for 1.5 h in the incubator (37 °C,
5% CO2). Voltage gated calcium channel (VGCC) blocker
cocktail (ω-conotoxin MVIIC [0.5 μM], SNX482
[0.15 μM], ω -agatoxin IVA [0.1 μM], nimodipine
[20 μM], and mibefradil [10 μM]) and Ro 25–6891 were
added to some cultures 30 min before the imaging and
not washed off. The fluorescence intensity of each well
was monitored every 1.28 s for 60 s. HBSS-Hepes buffer
containing various concentrations of NMDA was applied
16 s after the beginning of the recording. For each well,
the maximal fluorescence increase (ΔF) was normalized to
the baseline fluorescence (F0). The ΔF/F0 ratio of each
well was divided by the average ΔF/F0 ratio of wells
treated with ionomycin (1 μM).
Western blot analysis
Equal amounts of total protein (15 μg per lane) in 1×
NuPAGE LDS sample buffer (Thermo Fisher Scientific,
NP0007) and 1× Sample Reducing Agent (Thermo
Fisher Scientific, NP0009) were loaded per gel lane. Pro-
tein samples were electrophoresed on NuPAGE Novex
4–12% Bis-Tris Midi protein gels (Thermo Fisher Scien-
tific, WT1403A) in 1X NuPAGE MOPS SDS running
buffer (Thermo Fisher Scientific, NP0001–02) at 200 V
for 1 h at RT. Gels were transferred to nitrocellulose
membranes with an iBlot gel transfer device (Thermo
Fisher Scientific). Membranes were blocked with Odys-
sey blocking buffer (LI-COR, 927–40000) for 1 h at RT,
incubated with primary antibodies overnight at 4 °C,
washed with TBS containing 0.05% Tween20 (TBST)
four times for 5 min at RT, incubated with matching sec-
ondary antibodies conjugated to IRDye (LI-COR, 0.1 μg/
mL) for 1 h at RT, and washed in TBST four times for
5 min at RT. Protein bands were visualized with an
Odyssey CLx Infrared Imaging System (LI-COR) and
quantified with Image Studio software (LI-COR).
Generation of mTau mutants
A cDNA encoding WT 0N4R mTau was linked to a red-
shifted variant of GFP (RSGFP4) [115] via a P2A linker
that contained a furin cleavage site and a V5 tag [116] by
PCR. The resulting GFP-P2A-mTau construct was
inserted into a pFUW plasmid between AscI and RsrII
sites. A short sequence of mTau 3′ UTR (Fragment H)was inserted into this plasmid between RsrII and HpaI
sites. Fragment H is homologous to a 3′ UTR region of
rat tau that stabilizes tau mRNA and promotes its
axonal localization [117, 118]. The RsrII site between
mTau and Fragment H was deleted using the Quik-
change II XL site-directed mutagenesis kit (Agilent
Technologies 200522) and the following primers: 5′-
gatccggcgcgccatggtgagcaagg-3′ and 5′-ccttgctcac-
catggcgcgccggatc-3′. We refer to the resulting plasmid
as GFP-P2A-mTauWT. The GFP-P2A control plasmid
lacks the mTau cDNA and has a tga stop codon at the
3′ end of the P2A linker. The Quikchange II XL site-
directed mutagenesis kit was used to introduce muta-
tions into GFP-P2A-mTauWT using the primers listed in
Table 3.
After mutagenesis, plasmids were validated by se-
quence analysis and used to transform the Stbl3 E. coli
strain (Thermo Fisher Scientific, C7373–03) for main-
tenance. The constructs encoding mTaunoRD or mTau8RD
were described previously [68].
Production and purification of lentiviral particles
Lentiviral particles were generated by co-transfecting the
transfer vector (pFUGW containing shSCR or shTau,
and pFUW containing GFP-P2A, GFP-P2A-mTauWT, or
GFP-P2A-mTau with mTau mutations), the HIV-1 pack-
aging vector (Delta8.9), and the VSVG envelope glyco-
protein expression vector (pVSVG) into HEK293T cells.
Confluent HEK293T cells were transfected with 22.5 μg
of transfer vector, 16.9 μg of Delta8.9, and 11.25 μg of
pVSVG per 15 cm petri dish using CalPhos transfection
reagent (Clontech, 631312) according to the manufac-
turer’s instructions. Medium containing lentiviral parti-
cles was collected 48 h after transfection and filtered
through a 0.22-μm cellulose acetate filter (Corning In-
corporated, 431154). Lentiviral particles in the medium
were then concentrated by serial ultracentrifugation:
21,000 rpm for 2 h at 4 °C in a Beckman SW28 and then
25,000 rpm for 2 h at 4 °C in a Beckman SW55 with a
sucrose cushion consisting of 2 ml of 20% sucrose in
Hank’s balanced salt solution (HBSS, Thermo Fisher
Scientific, 14170) at the bottom of the SW55 tubes. Final
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-80 °C until use. Lentiviral titers were determined with a
p24 ELISA. Neuronal cultures were transduced with len-
tiviral particles encoding shRNA at 3 fg p24 per neuron
on the day of plating (DIV0) or with lentiviral particles
encoding mTau at 0.02 pg p24 per neuron on DIV7.
Lentiviral vectors encoding shRNA against mTau were
described previously [68]. Briefly, the target sequence for
the anti-tau shRNA was 5′- acagagtccagtcgaagatt -3′.
The shRNA was placed under control of the U6 pro-
moter. The U6-shRNA expression cassette (pSilencer
2.0, Ambion) was inserted between the NheI and PacI
sites of pFUGW plasmid, upstream of a ubiquitin C pro-
moter directing expression of EGFP. A similar construct
expressing an shRNA targeting a scrambled sequence
(5′- ccactaccgttgttataggtg -3′) was used as a control.
Proximity Ligation Assay (PLA)
On DIV 7, 106 neurons from Mapt−/− P0–P1 pups
were plated on 12-mm poly-D-lysine/laminin-coated
glass coverslips (BD Biosciences, 354087), incubated
in Neurobasal A medium containing kynurenic acid
(1 mM, Sigma-Aldrich, K3375-5G) and GlutaMAX
(0.5 mM, Thermo Fisher Scientific, 35050–061) at 37o
C with 5% CO2 for 30–60 min, and transfected with
pFUW plasmids encoding GFP-P2A or GFP-P2A-mTau.
To prepare the transfection mixture, each plasmid (1.0 μg
per coverslip) was dissolved in 50 μl Opti-MEM (Thermo
Fisher Scientific, 31985–062), mixed with 50 μl Opti-
MEM containing 1.35 μl Lipofectamine 2000 (Thermo
Fisher Scientific, 11668–027), and incubated for 20 min at
RT. Neuronal cultures were incubated in the transfection
mixture for 30 min at 37o C with 5% CO2. Cultures were
then washed with pre-warmed PBS once and placed back
into conditioned medium collected from the same cul-
tures before transfection. PLA was performed according
to the protocol of Duolink In Situ/Fluorescence (Sigma-
Aldrich) one day after transfection. Neurons were fixed
with 4% paraformaldehyde/4% sucrose in 1× PBS for
15 min at RT, washed with 1× PBS (3 × 5 min), perme-
abilized with 0.2% Triton X-100 in 1× PBS for 5 min, and
blocked with 5% normal goat serum (NGS, Jackson
Immunoresearch, 005–000–121) in 1× PBS for 30 min at
RT. They were then incubated with primary antibodies
(Tau1: 1 μg/ml, Tau5: 2 μg/ml, Fyn3: 4 μg/ml) in 1% NGS/
1× PBS at 4 °C overnight. After washing with 1× PBS
(3 × 5 min), neurons were incubated with two PLA probes
(Duolink In Situ PLA Probe Anti-Rabbit PLUS
DUO92002 and Duolink In Situ PLA Probe Anti-Mouse
MINUS DUO92004, Sigma-Aldrich) in 1% NGS/1× PBS
for 1 h at 37 °C, followed by washes (2 × 5 min) with 1×
Wash Buffer A (Sigma-Aldrich, DUO82049-4 L) and incu-
bation in ligation solution (Sigma-Aldrich, Duolink In Situ
Detection Reagents Red, DUO92008) for 1 h at 37 °C.After ligation of complementary PLA probes that were in
close (<40 nm) proximity, neurons were washed with 1×
Wash Buffer A (2 × 2 min) and incubated in the amplifi-
cation solution (Sigma-Aldrich, Duolink In Situ Detection
Reagents Red, DUO92008) for 100 min at 37 °C to fluo-
rescently label the ligated PLA probes. Neurons were then
serially washed in 1× Wash Buffer B (2 × 10 min, Sigma-
Aldrich, DUO82049-4 L), 0.01× Wash Buffer B
(1 × 1 min), and 1× PBS (1 × 5 min), followed by incuba-
tion with secondary antibodies (Thermo Fisher Scientific,
Alexa-Fluor647 Goat anti Mouse, A21235) in 1% NGS/1×
PBS for 1 h at RT. Finally, neurons were washed with 1×
PBS (3 × 5 min) and mounted in Duolink In Situ Mount-
ing Medium with DAPI (Sigma-Aldrich, DUO 82040).
Fluorescent images were obtained with an epifluorescence
microscope (Nikon Ti-E Microscope, Nikon Imaging Cen-
ter at UCSF). The intensity of PLA signals, Tau1 and Tau5
immunoreactivity, and GFP fluorescence within neuronal
processes were quantitated with the NIS elements soft-
ware (Nikon). Since PLA signals correlated with the ex-
pression levels of mTau (Additional file 4: Figure S4C),
they were normalized to colocalized Tau1 or Tau5 im-
munofluorescence to calculate the affinity of each mTau
mutant to Fyn.Statistical analysis
Experimenters were blinded with respect to the geno-
type and treatment of cell cultures. Biological units were
randomized during assays, sampling and analyses.
Statistical analyses were performed with Prism (Ver. 6,
GraphPad) or R (R Development Core Team, http://
www.R-project.org/). Individual experiments (glutamate-
induced excitotoxicity assay, live Ca2+ imaging, high-
content imaging assay, and western blot analysis) or
individual transfected neurons (PLA) were treated as in-
dependent units (n). Across experiments/plates, neurons
of the same genotype that were exposed to the same ex-
perimental condition showed a reasonably consistent,
dose-dependent change in alamarBlue signal or intracel-
lular Ca2+ signal upon treatment with glutamate or other
drugs. However, across experiments/plates we observed
systematic variations in the mean and variance of neur-
onal responses as well as in the shapes of dose-response
curves (Additional file 3: Figure S3). Therefore, we con-
sidered different wells on the same plate technical repli-
cates and defined independent experiments as
independent units (n) for statistical analysis. To analyze
data obtained in multiple experiments, differences in the
mean fluorescence signal intensities obtained by alamar-
Blue or Ca2+ imaging in wells containing experimentally
altered cells (e.g., transduced with shTau) versus control
cells (e.g., transduced with shSCR) on the same plate
were computed for each dose of glutamate or another
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the above differences at each dose was less than or equal
to 0 across experiments/plates. To compare two differ-
ent experimental conditions across different doses of
glutamate, we calculated a p-value for an overall
interaction between two conditions and dose from a
one-sided, one-sample t-test performed on the mean dif-
ference in alamarBlue or intracellular Ca2+ signal inten-
sities between the two experimental conditions across all
doses. The above statistical approach was selected
because it is non-parametric, and thus does not assume
any particular systematic variation in the responses
among experiments/plates or any particular parametric
shape of the dose response curve. In other experiments,
differences between genotypes and treatments were
assessed, as appropriate, by unpaired Student’s t-test
with Welch’s correction or by one-way ANOVA. The
null hypothesis was rejected at P < 0.05. Quantitative
data are presented as boxplots or means ± SEM.
Additional files
Additional file 1: Figure S1. DNQX and TTX were bioactive. (A–C)
Experiments illustrating effects of DNQX (A) and TTX (B, C). (A) A single
experiment was performed to confirm that DNQX blocks AMPA-induced
neurotoxicity in primary neuronal cultures. Data represent means ± SEM
of technical replicates (4–6 wells per condition). WT neurons were treated
with vehicle or the competitive AMPAR antagonist DNQX (20 μM) 1 h
before and throughout exposure to different concentrations of AMPA.
Raw AlamarBlue fluorescence measurements are shown in arbitrary units.
(B, C) TTX blocked spontaneous and induced neuronal activity in acute
brain slices. Slices of somatosensory cortex were prepared and pyramidal
neurons were patch-clamped as described [9]. Whole-cell membrane
voltage recordings were made in artificial cerebrospinal fluid (aCSF) in
the absence or presence of 3 μM TTX (from the same batch used for cell
culture experiments). (B) TTX prevented spontaneous neuronal activity as
well as activity induced by 100 pA/200 ms current stimulations
(arrowheads) or by a membrane voltage ramp (between asterisks). Scale
bar indicates 20 s of recording time. (C) Representative membrane
voltage responses elicited by 100 pA/200 ms current stimulations in
control aCSF and after addition of 3 μM TTX. (PDF 4818 kb)
Additional file 2: Figure S2. Glutamate-induced neurotoxicity depends
on NMDARs and extracellular Ca2+. (A, B) Experiments illustrating Ca2+
dependence of glutamate-induced neurotoxicity (A) and neurotoxicity
caused by different glutamate receptor agonists (B). (A) One experiment
was performed to confirm that reduction of extracellular Ca2+ counteracts
glutamate-induced neurotoxicity. WT neurons were treated with
Ca2+-containing isotonic solution or 0 mM Ca2+ solution 1 h prior to and
throughout exposure to different concentrations of glutamate. Raw
AlamarBlue fluorescence measurements are shown in arbitrary units. (B)
Neurotoxicity was assessed as above in WT neuronal cultures treated with
the indicated glutamate receptor agonists for 15 min at DIV 13. Data
represent means ± SEM of technical replicates (8–16 wells per condition)
from 1 to 2 experiments. (PDF 4803 kb)
Additional file 3: Figure S3. Variability of glutamate-induced
neurotoxicity measurements across independent experiments. In each of
seven independent experiments (carried out on different days), primary
neurons pooled from multiple WT mice were cultured on a single 96-well
plate and transduced with lentiviral vectors encoding shSCR or shTau
(44–48 wells per shRNA) at the time of plating (DIV0). On DIV 13, neurons
were exposed to glutamate (4–8 wells per concentration) for 15 min,
followed by alamarBlue assay of neurotoxicity 24 h later. Different from the
other figures, the box plots shown here represent the distribution of theraw fluorescence signals (in arbitrary units) measured in each set of wells
(technical replicates) per glutamate concentration for each experimental
condition (shSCR and shTau) and experiment (1–7). The lower and upper
ends of the boxes represent the 25th and 75th quartile of the respective
distributions. The horizontal line in each box represents the median. The
ends of the whiskers terminate at the farthest points that are within 1.5
times the inter-quartile range (difference between upper and lower ends of
the box). Individual dots shown in some of the panels represent outliers that
fell outside the range defined by the whiskers. Note that, across experiments,
neurons of the same genotype that were exposed to similar experimental
conditions showed systematic variations in the mean and variance of their
responses at given doses as well as in the shapes of their dose-response
curves. Therefore, accounting for experiment-to-experiment variability by
mean models of intensity (e.g., linear mixed effect models) and minimizing
the number of dose-specific parameters to be estimated by assuming dose-
response models (e.g., linear, cubic, or Hill) were not suitable for the analysis
of this data. (PDF 4937 kb)
Additional file 4: Figure S4. Proximity ligation assay (PLA) to
quantify association between tau and Fyn in neurons. (A) Diagram
illustrating key features of the PLA assay. Neuronal cultures from
Mapt−/− mice were transfected on DIV7 with a plasmid encoding
GFP-P2A or GFP-P2A-mTau and fixed for PLA and immunostaining on
DIV8. The GFP-P2A-mTau fusion protein is posttranslationally cleaved
at the C-terminal side of the P2A peptide, resulting in the production
of GFP-P2A and mTau at a 1:1 molar ratio. The mTau expressed was
either WT or mutant (Fig. 5a). GFP signals were used to identify
transfected neurons and PLA signals to measure the association
between exogenous mTau and endogenous Fyn (see Methods for
details). mTau immunofluorescence was used to normalize PLA
signals, because mTau expression levels varied among neurons and
correlated with PLA signals, as indicated in (C). (B, C) Neurons were
transfected with plasmids encoding GFP-P2A, GFP-P2A-mTauWT, or
GFP-P2A-mTauAxxA7 on DIV7 and analyzed by PLA and tau immunostaining
on DIV8. (B) Representative photomicrographs showing levels of GFP signals
(left), PLA signals (middle), and tau immunoreactivity (right) in three neurons
from different culture wells. Scale bar: 50 μm. (C) Correlation between PLA
signals and Tau5 immunofluorescence across individual neurons in cultures
transfected with GFP-P2A-mTauWT (black: R2 = 0.6436, P < 0.0001) or GFP-
P2A-mTauAxxA7 (red: R2 = 0.3098, P < 0.0001) by linear regression analysis.
Neurons transfected with GFP-P2A (gray) served as a negative control. Data
points represent measurements obtained in individual neurons (mean of
signals from three neurites per neuron) on two coverslips in a single
experiment. (PDF 7504 kb)
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